Oruka Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, null, null, 75.58 ], "ebit_estimate": [ -159.66, -200.84, -279.77, -355.26, -260.45 ], "ebitda_estimate": [ -149.98, -172.82, -226.16, null, null ], "net_income_estimate": [ -141.56, -179.75, -265.05, -349.38, -391.59 ], "per_share_eps_estimate": [ -2.04, -2.5, -3.52, -4.44, -4.87 ], "eps_nri_estimate": [ -2.07, -2.53, -3.5, -4.4, -4.93 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 14.32, 12.42, 10.58, null, null ], "pretax_income_estimate": [ -142.55, -184.01, -265.05, -349.38, -242.79 ], "operating_cash_flow_per_share_estimate": [ -1.7, -1.63, -2.32, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -16.54, -12.58, -20.25, null, null ], "gross_margin_estimate": [ null, null, null, null, 95 ], "operating_cash_flow_estimate": [ -94.03, -90.16, -128.32, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -23.47, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -23.77, "future_eps_nri_estimate_growth": -23.47, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -31.23, "future_ebitda_estimate_growth": -27.55, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -35.04, "future_pretax_income_estimate_growth": -35.27, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, null, null ], "ebit_estimate": [ -38.74, -50.99, -44.16, -47.13, -49.58, -53.62, -59.91 ], "ebitda_estimate": [ null, null, null, null, null, null, null ], "net_income_estimate": [ -34.92, -35.89, -38.09, -42.81, -45.33, -49.43, -55.79 ], "per_share_eps_estimate": [ -0.51, -0.51, -0.55, -0.58, -0.62, -0.65, -0.69 ], "eps_nri_estimate": [ -0.52, -0.52, -0.55, -0.59, -0.63, -0.66, -0.7 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -35.01, -36.33, -38.7, -46.24, -49.44, -54.74, -63.06 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -23.47, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -23.77, "future_eps_nri_estimate_growth": -23.47, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -31.23, "future_ebitda_estimate_growth": -27.55, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -35.04, "future_pretax_income_estimate_growth": -35.27, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }